Actively Recruiting
Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients A Single Centre Randomized Controlled Trial
Led by Hamad Medical Corporation · Updated on 2025-12-29
22
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the effect of scalp blocks on reducing headaches in patients who have suffered an aneurysmal subarachnoid hemorrhage (aSAH) and are undergoing endovascular treatment of their aneurysm. aSAH is a serious neurological condition caused mostly by ruptured brain aneurysms, leading to significant health complications and a high rate of headache-related hospital readmissions. There is currently limited evidence guiding the management of these headaches, which can persist for years and impact quality of life and recovery. The study compares two groups: one receiving a scalp block with 20 ml of 0.5% Levobupivacaine administered after the endovascular procedure but before extubation, alongside conventional pain management; and a control group receiving only conventional analgesic therapy, including regular intravenous paracetamol and fentanyl patient-controlled analgesia. The scalp block targets specific nerves around the scalp to potentially alleviate headache pain. This is a single-center, randomized controlled trial. Participants will be monitored for total opioid consumption and pain scores in the first 24 hours after receiving the scalp block or conventional therapy. Researchers will assess the impact of the block on headache severity and opioid use. The study involves critical care monitoring in the Surgical Intensive Care Unit, with safety checks for allergic reactions or complications. The total participation duration centers around the immediate post-procedure period and the first day afterward to measure outcomes.
CONDITIONS
Brief Title
Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults over 18 years old
- Admitted to the Surgical Intensive Care Unit with confirmed aneurysmal subarachnoid hemorrhage
- Undergoing endovascular treatment of the aneurysm, such as coiling or flow diversion
You will not qualify if you...
- Undergoing surgical craniotomy and aneurysmal clipping
- Having non-aneurysmal subarachnoid or other intracranial hemorrhages
- Glasgow Coma Scale score of 13 or lower at ICU admission
- WFNS Score 4 or 5, or requiring mechanical ventilation for more than 24 hours
- Known allergy to local anesthetics
- ICU admission more than 7 days after hemorrhage
- Documented bleeding disorders
- History of chronic headache disorder or migraine
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 hours after the intervention
Participants undergo endovascular treatment of the aneurysm and receive either a scalp block with Levobupivacaine in addition to conventional pain management or conventional pain management alone to manage post-subarachnoid hemorrhage headaches.
1 procedure visit and monitoring during the first 24 hours
Trial Site Locations
Total: 1 location
1
Hamad Medical Corporation
Doha, Qatar
Actively Recruiting
Research Team
S
Sohel Mohamed Ahmed, Consultant
A
Abdelrahman Balal, Clinical Fellow
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here